LYD-HM16D | 价格

LYD-HM16D-100μg / 询价

LYD-HM16D-500μg / 询价

LYD-HM16D-500μgx2 / 询价

Human LY6G6D Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Human LY6G6D Protein is expressed from HEK293 with His tag and Strep-II tag at the C-Terminus.
It contains Asn20-Ser104 [Accession | O95868].

分子量大小(Molecular Weight)

The protein has a predicted MW of 12.33 kDa. Due to glycosylation, the protein migrates to 15-20 kDa based on Bis-Tris PAGE result.

纯度(Purity)

> 95% as determined by Bis-Tris PAGE

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

制剂(Formulation)

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Bis-Tris PAGE

Human LY6G6D on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Immobilized Human LY6G6D, His Tag at 0.2μg/ml (100μl/well) on the plate. Dose response curve for Anti-LY6G6D Antibody, hFc Tag with the EC50 of 2.1ng/ml determined by ELISA.

背景(Background)

LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.LY6G6D was identified as a selectively expressed CRC antigen that can be utilized to potently re-direct and activate cytotoxic T-cells to lyse LY6G6D expressing CRC using a TcE. This effect can be spread to target negative neighboring tumor cells, potentially leading to improved therapeutic efficacy.

分子别名(Synonyms)

Protein Ly6-D; C6orf23; G6D; MEGT1; NG25

文献(References)

Corrales L, Hipp S, Martin K, Sabarth N, Tirapu I, Fuchs K, Thaler B, Walterskirchen C, Bauer K, Fabits M, Bergmann M, Binder C, Chetta PM, Vogt AB, Adam PJ. LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager. Front Immunol. 2022 Sep 8;13:1008764. doi: 10.3389/fimmu.2022.1008764. PMID: 36159851; PMCID: PMC9493073.